Brief: Equasens Says Growth Momentum Of Pharmagest Division Remains Solid
09/11/2023 17:11
Nov 9 (Reuters) - Equasens SA EQSE.PA :
* 2023 OUTLOOK: EXCLUDING COMPARISON BASE EFFECT FROM END OF
SÉGUR
DEPLOYMENT IN 2022 AND ITS EXCEPTIONAL CONTRIBUTION TO REVENUE,
GROWTH MOMENTUM OF PHARMAGEST DIVISION'S REMAINS SOLID
* OUTLOOK 2023: AXIGATE LINK AND E-CONNECT DIVISIONS ARE
ALSO
CONFIDENT THAT THEIR GROWTH LEVELS WILL REMAIN STRONG FOR
REMAINDER OF YEAR
* OUTLOOK 2023: THE MEDICAL SOLUTIONS DIVISION IS CURRENTLY
RESTRUCTURING ITS OFFERING AND ORGANIZATION IN ORDER TO ENHANCE
ITS PERFORMANCE
* OUTLOOK 2023: BASED ON THE POSITIVE RESULTS OF A MAJOR
BUSINESS
DEVELOPMENT CAMPAIGN, THE FINTECH DIVISION IS CONFIDENT ABOUT
ITS OUTLOOK FOR YEAR-END
* OUTLOOK 2023: GROUP WILL CONTINUE TO BE ON THE LOOKOUT FOR
EXTERNAL GROWTH OPPORTUNITIES IN FRANCE AND EUROPE
Source text for Eikon: ID:nGNE2m7TKT
Further company coverage: EQSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))